Our subgroup analysis indicated that patients with a PD-L1 CPS of 10 or above and those not initially diagnosed with metastatic disease were notably more inclined to achieve cost-effective results than their counterparts in other subgroups. Here, CD274 is linked to metastatic neoplasm.